Neuraminidase is one of the two surface glycoproteins of influenza A and B viruses. It has
enzymatic activity that cleaves terminal sialic acid from glycans, and that activity is essential …

Highlights•Neuraminidase (NA)-inhibiting antibodies are an independent correlate of
vaccine efficacy.•Many NA-specific antibodies bind to conserved epitopes and protect …

Neuraminidase (NA) is an influenza surface protein that helps to free viruses from mucin-
associated decoy receptors and to facilitate budding from infected cells. Experiments have …

Neuraminidase of influenza A and B viruses plays a critical role in the virus life cycle and is
an important target of the host immune system. Here, we highlight the current understanding …

Despite the availability of vaccine prophylaxis and antiviral therapeutics, the influenza virus
continues to have a significant, annual impact on the morbidity and mortality of human …

Vaccines are instrumental in controlling the burden of influenza virus infection in humans
and animals. Antibodies raised against both major viral surface glycoproteins …

Neuraminidase (NA) is the second most abundant influenza surface glycoprotein and
contributes to virus replication in several ways, most notably by removing sialic acids from …

For 50 years it has been known that antibodies to neuraminidase (NA) protect against
infection during seasonal and pandemic influenza outbreaks. However, NA is largely …

There is growing appreciation for neuraminidase (NA) as an influenza vaccine target;
however, its antigenicity remains poorly characterized. In this study, we isolated three …

Antibodies to the hemagglutinin (HA) and neuraminidase (NA) glycoproteins are the major
mediators of protection against influenza virus infection. Here, we report that current …